编号：2018-005 证券代码：002562 证券简称：兄弟科技 兄弟科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------------|--------------------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 太平洋证券 杨伟 东兴证券 洪翀 | | | 人员姓名 | 鼎天投资 杨日平 | | | 时间 | 2018 年 11 月 16 日 | | | 地点 | 兄弟科技会议室 | | | 上市公司接待人 | 董事会秘书 钱柳华 | | | 员姓名 | | | | 投资者关系活动 | | 调研公司发展和行业情况（以投资者提问，公司高管回答的方式展开） | | 主要内容介绍 | ...

Group 1: Vitamin K3 Insights - The production of Vitamin K3 is linked to chromium tanning agents; if the tanning agents are not strong, it negatively impacts Vitamin K3 production [2] - Current industry competition suggests limited potential for new entrants or expansions in Vitamin K3 production [2] - Rising costs due to poor downstream conditions for chromium tanning agents and increased import prices for chromium ore are expected to positively influence Vitamin K3 prices in the future [3] Group 2: Vitamin B5 and Market Position - As a new manufacturer, the company will follow market pricing trends for Vitamin B5 [3] Group 3: Strategic Industry Entry - The company has chosen to enter the iodine contrast agent market based on strategic considerations, including downstream customer overlap, existing channels, competitive landscape, and production technology [3] - A dedicated pharmaceutical division has been established to develop the iodine contrast agent business [3] Group 4: Future Planning - The company's future focus will be on raw materials, pharmaceuticals, and flavors/fragrances to reduce product cyclicality [3] - The company has recruited talent in the fragrance and pharmaceutical sectors and is working on core product identification and upstream/downstream planning [3] - Plans include accelerating the development of the Brother Pharmaceutical strategic base and exploring strategic partnerships, acquisitions, and mergers to extend the product value chain and enrich product structure [3]

Group 1: Company Overview and Strategic Development - In the past three years, Brother Technology has accelerated its layout, expanding from leather chemicals and vitamins to include flavors and pharmaceuticals, with core projects in these new sectors officially launched in the second half of last year [1] - The company's first active pharmaceutical ingredient (API) product was Vitamin B1, with plans to introduce additional vitamin products [1] Group 2: Product Development and Production Capacity - The company aims to supply API-grade vitamin products through multifunctional workshops, with iodine contrast agents as a core product, and plans to produce specialty and patented APIs [3] - The first phase of the "20,000 tons of phenol and 31,100 tons of phenol derivatives" project was launched in October last year, with products gradually entering the market [3] - The "30,000 tons of natural flavor construction project" is scheduled to officially start construction in the first half of this year [3] Group 3: Market Position and Customer Base - The iodine contrast agent is chosen due to its large volume, rapid growth, and favorable supply structure, leveraging the company's well-established infrastructure in Jiujiang [3] - Current customers for iodine contrast agent intermediates include both domestic and international clients [3]

证券代码：002562 证券简称：兄弟科技 兄弟科技股份有限公司 投资者关系活动记录表 编号：2021-001 | --- | --- | --- | --- | --- | --- | --- | |----------------|--------------------------------------------------------------------|----------------------------|-------|-------|----------------|-------| | | | | | | | | | | ■ 特定对象调研 | □ 分析师会议 | | | | | | 投资者关系活动 | □ 媒体采访 | □ 业绩说明会 | | | | | | 类别 | □ 新闻发布会 | □ 路演活动 | | | | | | | □ 现场参观 □ | 其他 | | | | | | 参与单位名称及 | 光大保德信基金经理 黄波 | | | | | | | 人员姓名 | 安信证券股份有限公司 朱梦天 | | | | | | | 时间 | 2021 年 2 月 2 日星期二下午 3 点 ...

证券代码：002562 证券简称：兄弟科技 兄弟科技股份有限公司投资者关系活动记录表 编号：2021-002 | --- | --- | --- | |----------------|------------------------------------------|------------------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 首创证券股份有限公司 赵晨曦 | | | 人员姓名 | 上海德汇集团有限公司 田益铭 | 夏步刚 | | 时间 | 2021 年 2 月 24 日 10 点 | | | 地点 | 202 会议室 | | | 上市公司接待人 | 高级副总裁/董事会秘书 | 钱柳华 | | 员姓名 | 证券专员 王超 | | | | 1 势？ | ...

编号：2021-005 证券代码：002562 证券简称：兄弟科技 兄弟科技股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|--------------| | | | | | | 投资者关系活动 | ■特定对象调研 | □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | 参与单位名称及 | 东腾创新投资股份有限公司（ | Athena Capital Management | ）王安亚 ...

证券代码：002562 证券简称：兄弟科技 兄弟科技股份有限公司投资者关系活动记录表 编号：2022-001 | --- | --- | --- | |-----------------------|----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | ■特定对象调研 | □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称 | | 国盛证券、申银万国、诺安基金、中银基金、上投摩根、国泰基金、太平 | | | | 资产、太平养老、农银汇理、东证资管、国寿资产、工银安盛、星石投资 ...

证券代码：002562 证券简称：兄弟科技 编号：2022-003 | --- | --- | --- | |-----------------------|-----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------| | | ■特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | | | 中泰证券；泰达宏利；农银汇理；红土创新；阳光资产；中庚基金；慧琛 | | 参与单位名称 | （以上排名不分先后） | 私募；光大保德信；交银施罗德金管理；益民基金；南方基金；申九资产； 凯丰投资；光大永明资管；康曼德资本；人保资产。 | | 时间 | 20 ...

编号：2022-005 证券代码：002562 证券简称：兄弟科技 兄弟科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------------------|------------------------------------------------------------------| | | □特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 ■业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 形式 | □现场 ■网上 □电话会议 | | | 参与单位名称 | 线上参与公司 2021 | 年度网上业绩说明会的投资者 | | 时间 | 2022 年 05 月 17 日 | 15:00-17:00 | | 地点 | 价值在线（ | https://www.ir-online.cn/ ） | | | 董事长/总裁 钱志达 | | | | 财务中心总监 张永辉 | | | 上市公司接 ...

Group 1: Company Overview - Brothers Technology Co., Ltd. has over 30 years of experience in the fine chemical industry, initially focusing on leather chemicals and vitamins, and has expanded into four major sectors: vitamins, flavors and fragrances, pharmaceuticals, and specialty chemicals [1] - The company has established four production bases located in Haining, Yancheng, and other regions, continuously developing its vitamin and specialty chemicals sectors [1] Group 2: Impact of COVID-19 - The Haining base was slightly affected by local COVID-19 restrictions, while other bases remained unaffected [2] - Logistics faced challenges in efficiency due to the pandemic, but the company managed to mitigate impacts through increased inventory and better logistics planning [2] Group 3: Future Investment Plans - The company plans to focus on existing products in the vitamin and specialty chemicals sectors, enhancing supply chain, technological innovation, and global marketing [2] - For the flavors and fragrances and pharmaceutical sectors, the company aims to accelerate production capacity release and project profitability [2] Group 4: Project Changes - The company has decided to change its pine oil project to a second phase of the phenol project due to rising market prices of pine oil, which could negatively impact economic benefits [2] - The first phase of the phenol project is currently operational, and the second phase will leverage existing infrastructure and expertise [2] Group 5: Raw Material Drug Progress - The iodine contrast agent project has commenced production, focusing on intermediate sales while awaiting regulatory approvals for market entry [3] - The company is also exploring specialty and patented raw materials to enhance its pharmaceutical platform [3] Group 6: Customer Base and Market Applications - The flavors and fragrances sector overlaps significantly with existing vitamin product applications, serving industries such as food, daily chemicals, and pharmaceuticals [3] - The phenol product is widely used in various applications, with the polymerization inhibitor sector being the largest market [3] Group 7: Financial Performance - Brothers CISA, a subsidiary, turned a profit in 2021 with a net profit of 26.67 million yuan, despite facing challenges from rising raw material and logistics costs [3] - The company is considering the potential redemption of its convertible bonds based on future performance and regulatory requirements [3]